PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 52 | 2 | 285-291
Article title

Targeting site-specific chromosome integration.

Content
Title variants
Languages of publication
EN
Abstracts
EN
The concept of gene therapy was introduced with great promise and high expectations. However, what appeared simple in theory has not translated into practice. Despite some success in clinical trials, the research community is still facing an old problem: namely, the need for a vector that can deliver a gene to target cells without adverse events while maintaining a long-term therapeutic effect. Some of these challenges are being addressed by the development of hybrid vectors which meld two different viral systems to incorporate efficient gene delivery and large cloning capacity with site-specific integration. The two known systems that integrate genes into specific sites in mammalian genomes are the adeno-associated virus and phage integrases. Recent experiments with hybrid vectors incorporating both of these systems are encouraging. However, extensive research should be directed towards the safety and efficacy of this approach before it will be available for gene therapy.
Publisher

Year
Volume
52
Issue
2
Pages
285-291
Physical description
Dates
published
2005
received
2005-04-13
revised
2005-04-19
accepted
2005-05-31
(unknown)
2005-06-03
Contributors
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
author
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA
author
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
References
  • Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
  • Amiss TJ, McCarty DM, Skulimowski A, Samulski RJ. (2003) Identification and characterization of an adeno-associated virus integration site in CV-1 cells from the African green monkey. J Virol 77: 1904-1915.
  • Balter M. (2000) Gene therapy on trial. Science 288: 951-957.
  • Belteki G, Gertsenstein M, Ow DW, Nagy A. (2003) Site-specific cassette exchange and germline transmission with mouse ES cells expressing phiC31 integrase. Nat Biotechnol 21: 321-324.
  • Burcin MM, Schiedner G, Kochanek S, Tsai SY, O’Malley BW (1999) Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 96: 355-360.
  • Cavazzana-Calvo M, Hacein-Bey S, De Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
  • Check E (2003) Cancer fears cast doubts on future of gene therapy. Nature 421: 678.
  • Check E (2005) Gene therapy put on hold as third child develops cancer. Nature 433: 561.
  • Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O (1999) Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 10: 2481-2494.
  • Couzin J, Kaiser J (2005) Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 307: 1028.
  • Crystal RG (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404-410.
  • Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell-Thompson M, Daly T, Sands MS (2001) Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 8: 1343-1346.
  • Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ (2004) Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 78: 6556-6566.
  • Duan D, Yue Y, Yan Z, Engelhardt JF (2000) A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med 6: 595-598.
  • Dutheil N, Yoon-Robarts M, Ward P, Henckaerts E, Skrabanek L, Berns KI, Campagne F, Linden RM (2004) Characterization of the mouse adeno-associated virus AAVS1 ortholog. J Virol 78: 8917-8921.
  • Friedmann T (1996) Human gene therapy - an immature genie, but certainly out of the bottle. Nat Med 2: 144-147.
  • Goncalves MA, Pau MG, De Vries AA, Valerio D (2001) Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors. Virology 288: 236-246.
  • Groth AC, Calos MP (2004) Phage integrases: biology and applications. J Mol Biol 335: 667-678.
  • Groth AC, Olivares EC, Thyagarajan B, Calos MP (2000) A phage integrase directs efficient site-specific integration in human cells. Proc Natl Acad Sci USA 97: 5995-6000.
  • Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
  • Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Mccormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, De Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
  • Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M (2005) In vivo correction of murine hereditary tyrosinemia type I by varphiC31 integrase-mediated gene delivery. Mol Ther 11: 399-408.
  • Hermonat PL (1992) Inhibition of bovine papillomavirus plasmid DNA replication by adeno-associated virus. Virology 189: 329-333.
  • Hollis RP, Stoll SM, Sclimenti CR, Lin J, Chen-Tsai Y, Calos MP (2003) Phage integrases for the construction and manipulation of transgenic mammals. Reprod Biol Endocrinol 1: 79.
  • Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, Mcclelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261.
  • Kimmelman J (2005) Recent developments in gene transfer: risk and ethics. BMJ 330: 79-82.
  • Kochanek S (1999) High-capacity adenoviral vectors for gene transfer and somatic gene therapy. Hum Gene Ther 10: 2451-2459.
  • Kotin RM, Linden RM, Berns KI (1992) Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11: 5071-5078.
  • Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, Mclaughlin S, Muzyczka N, Rocchi M, Berns KI (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215.
  • Kubo S, Mitani K (2003) A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol 77: 2964-2971.
  • Kumar M, Keller B, Makalou N, Sutton RE (2001) Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12: 1893-1905.
  • Lamartina S, Roscilli G, Rinaudo D, Delmastro P, Toniatti C (1998) Lipofection of purified adeno-associated virus Rep68 protein: toward a chromosome-targeting nonviral particle. J Virol 72: 7653-7658.
  • Li Z, Dullmann J, Schiedlmeier B, Schmidt M, Von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C (2002) Murine leukemia induced by retroviral gene marking. Science 296: 497.
  • Lieber A, Steinwaerder DS, Carlson CA, Kay MA (1999) Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J Virol 73: 9314-9324.
  • Linden RM, Ward P, Giraud C, Winocour E, Berns KI (1996) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93: 11288-11294.
  • Marshall E (1995) Gene therapy’s growing pains. Science 269: 1050, 1052-1055.
  • McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819-845.
  • Morgan RA, Anderson WF (1993) Human gene therapy. Annu Rev Biochem 62: 191-217.
  • Mulligan RC (1993) The basic science of gene therapy. Science 260: 926-932.
  • Nakai H, Storm TA, Kay MA (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 18: 527-532.
  • Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302.
  • Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E, Burgess SM, Grompe M, Kay MA (2005) Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79: 3606-3614.
  • Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9: 1647-1652.
  • Oka K, Chan L (2002) Recent advances in liver-directed gene therapy for dyslipidemia. Curr Atheroscler Rep 4: 199-207.
  • Oka K, Chan L (2004) Liver-directed gene therapy for dyslipidemia and diabetes. Curr Atheroscler Rep 6: 203-209.
  • Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Calos MP, Khavari PA (2003) PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther 14: 923-928.
  • Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA (2002) Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-1170.
  • Philpott NJ, Giraud-Wali C, Dupuis C, Gomos J, Hamilton H, Berns KI, Falck-Pedersen E (2002a) Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J Virol 76: 5411-5421.
  • Philpott NJ, Gomos J, Berns KI, Falck-Pedersen E (2002b) A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19. Proc Natl Acad Sci USA 99: 12381-12385.
  • Philpott NJ, Gomos J, Falck-Pedersen E (2004) Transgene expression after rep-mediated site-specific integration into chromosome 19. Hum Gene Ther 15: 47-61.
  • Pieroni L, Fipaldini C, Monciotti A, Cimini D, Sgura A, Fattori E, Epifano O, Cortese R, Palombo F, La Monica N (1998) Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. Virology 249: 249-259.
  • Quenneville SP, Chapdelaine P, Rousseau J, Beaulieu J, Caron NJ, Skuk D, Mills P, Olivares EC, Calos MP, Tremblay JP (2004) Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther 10: 679-687.
  • Recchia A, Parks RJ, Lamartina S, Toniatti C, Pieroni L, Palombo F, Ciliberto G, Graham FL, Cortese R, La Monica N, Colloca S (1999) Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 96: 2615-2620.
  • Recchia A, Perani L, Sartori D, Olgiati C, Mavilio F (2004) Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol Ther 10: 660-670.
  • Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10: 3941-3950.
  • Schmidt M, Afione S, Kotin RM (2000) Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J Virol 74: 9441-9450.
  • Soifer H, Higo C, Kazazian HH Jr, Moran JV, Mitani K, Kasahara N (2001) Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum Gene Ther 12: 1417-1428.
  • Soifer H, Higo C, Logg CR, Jih LJ, Shichinohe T, Harboe-Schmidt E, Mitani K, Kasahara N (2002) A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther 5: 599-608.
  • Sun L, Li J, Xiao X (2000) Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 6: 599-602.
  • Surosky RT, Urabe M, Godwin SG, Mcquiston SA, Kurtzman GJ, Ozawa K, Natsoulis G (1997) Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 71: 7951-7959.
  • Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4: 346-358.
  • Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP (2001) Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 21: 3926-3934.
  • Tobiasch E, Rabreau M, Geletneky K, Larue-Charlus S, Severin F, Becker N, Schlehofer JR (1994) Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol 44: 215-222.
  • Verma IM, Somia N (1997) Gene therapy - promises, problems and prospects. Nature 389: 239-242.
  • Weitzman MD, Fisher KJ, Wilson JM (1996) Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers. J Virol 70: 1845-1854.
  • Weitzman MD, Kyostio SR, Kotin RM, Owens RA (1994) Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 91: 5808-5812.
  • Williams DA, Baum C (2003) Medicine. Gene therapy - new challenges ahead. Science 302: 400-401.
  • Yant SR, Ehrhardt A, Mikkelsen JG, Meuse L, Pham T, Kay MA (2002) Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 20: 999-1005.
  • Young SM Jr, Samulski RJ (2001) Adeno-associated virus (AAV) site-specific recombination does not require a Rep-dependent origin of replication within the AAV terminal repeat. Proc Natl Acad Sci USA 98: 13525-13530.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv52i2p285kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.